. Author manuscript; available in PMC: 2023 Jun 27.

Published in final edited form as: Stroke Vasc Interv Neurol. 2022 May 20;2(5):e000163. doi: 10.1161/svin.121.000163

Table 3.

Association of a 1-Hour Treatment Delay with Different Outcomes at 90 Days in Patients Treated With Endovascular Therapy

	Unadjusted OR per 1-hour delay (95% CI)	Unadjusted ARD, % (95% CI)	Model 1		Model 2
	Unadjusted OR per 1-hour delay (95% CI)	Unadjusted ARD, % (95% CI)	aOR per 1-hour delay (95% CI)^*	aARD, % (95% CI)^*	aOR per 1-hour delay (95% CI)^*	aARD, % (95% CI)^*
Onset to reperfusion
mRS 0–1	0.89 (0.82 to 0.97)	−2.8 (−4.7 to −0.9)	0.89 (0.80 to 0.99)	−2.1 (−3.8 to −0.3)	0.89 (0.80 to 0.99)	−1.9 (−3.7 to −0.2)
mRS 0–2	0.89 (0.82 to 0.96)	−2.8 (−4.5 to −1.0)	0.88 (0.79 to 0.98)	−1.9 (−3.5 to −0.4)	0.89 (0.79 to 0.99)	−1.8 (−3.3 to −0.2)
mRS 0–3	0.90 (0.83 to 0.98)	−2.2 (− 3.8 to −0.5)	0.90 (0.81 to 0.99)	−1.7 (− 3.2 to −0.2)	0.91 (0.82 to 1.01)	−1.4 (− 2.9 to 0.1)

ARD indicates absolute risk difference; aARD, adjusted absolute risk difference; aOR, adjusted odds ratio; FI, final infarct; mRS, modified Rankin Scale; and OR, odds ratio.

Adjusted ORs and absolute risk differences in predicted probabilities by hour were estimated from logistic regressions. The study adjusted for age, sex, stroke severity as baseline National Institutes of Health Stroke scale, prestroke mRS, location of occlusion, and additionally for final infarct as FI_ASPECTS at 24—48 hours in Model 1 and for FI_VOLUME final infarct volume in Model 2.